Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9.
Ethnic differences in drug response have been extensively reported, and ethnicity has been suggested to be useful clinically as a predictor of drug response. Genetic polymorphisms in the genes encoding beta(1) adrenergic receptor (AR) and beta(2) AR, targets of beta AR antagonists, and in cytochrome P4502C9, the enzyme involved in warfarin metabolism, have the potential to explain some of the observed ethnic variability in drug response and to improve clinical practice.
Muszkat
M
M
Unit of Clinical Pharmacology, Department of Medicine, Hadassah University Hospital, Jerusalem, Israel. muszkatm@hadassah.org.il
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D044466:Asian People / Q000235:genetics; D044383:Black People / Q000235:genetics; D065729:Cytochrome P-450 CYP2C9; D020022:Genetic Predisposition to Disease / Q000208:ethnology*; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods; D010601:Pharmacology, Clinical / Q000379:methods; D011110:Polymorphism, Genetic; D011941:Receptors, Adrenergic / Q000235:genetics*; D044465:White People / Q000235:genetics
D011941:Receptors, Adrenergic; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases